Elkis H. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am. 2007;30:511–33.

Article  PubMed  Google Scholar 

Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;65:34–48.

Article  Google Scholar 

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216–29.

Article  PubMed  Google Scholar 

Kravariti E, Demjaha A, Zanelli J, Ibrahim F, Wise C, MacCabe JH, et al. Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study. Psychol Med. 2019;49:2100–10.

Article  PubMed  Google Scholar 

Yada Y, Yoshimura B, Kishi Y. Correlation between delay in initiating clozapine and symptomatic improvement. Schizophrenia Res. 2015;168:585–6.

Article  Google Scholar 

Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer J-P, Marder S, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019;80:18com12123.

Article  PubMed  Google Scholar 

Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30–4.

Article  PubMed  Google Scholar 

Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis. Am J Psychiatry. 2005;162:1785–804.

Article  PubMed  Google Scholar 

Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early Use of Clozapine for Poorly Responding First-Episode Psychosis. J Clin Psychopharmacol. 2007;27:369–73.

Article  CAS  PubMed  Google Scholar 

Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia. Neuropsychopharmacology. 2012;37:2515–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biol Psychiatry. 2014;75:e11–3.

Article  CAS  PubMed  Google Scholar 

Mouchlianitis E, Bloomfield MAP, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophrenia Bull. 2016;42:744–52.

Article  Google Scholar 

Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145–55.

Article  CAS  PubMed  Google Scholar 

Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204–15.

Article  PubMed  Google Scholar 

Bendikov I, Nadri C, Amar S, Panizzutti R, Demiranda J, Wolosker H, et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophrenia Res. 2007;90:41–51.

Article  Google Scholar 

Egerton A, Griffiths K, Casetta C, Deakin B, Drake R, Howes OD, et al. Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration. Neuropsychopharmacology. 2022;48:567–75.

Article  PubMed  PubMed Central  Google Scholar 

McCullumsmith R. Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Neuropsychopharmacology. 2002;26:368–75.

Article  CAS  PubMed  Google Scholar 

Afshari P, Myles-Worsley M, Cohen OS, Tiobech J, Faraone SV, Byerley W, et al. Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia. Complex Psychiatry. 2015;1:125–44.

Article  Google Scholar 

Bjørn-Yoshimoto WE, Underhill SM. The importance of the excitatory amino acid transporter 3 (EAAT3). Neurochemistry Int. 2016;98:4–18.

Article  Google Scholar 

Underhill SM, Ingram SL, Ahmari SE, Veenstra-VanderWeele J, Amara SG. Neuronal excitatory amino acid transporter EAAT3: Emerging functions in health and disease. Neurochemistry Int. 2019;123:69–76.

Article  CAS  Google Scholar 

Radhakrishnan S, Amara SG Cellular redox regulation by the neuronal glutamate and cysteine transporter, EAAT3. The FASEB Journal. 2022;36:fasebj.2022.36.S1.L7661.

Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, et al. Identification of Multiple Serine Racemase (SRR) mRNA Isoforms and Genetic Analyses of SRR and DAO in Schizophrenia and d-Serine Levels. Biol Psychiatry. 2005;57:1493–503.

Article  CAS  PubMed  Google Scholar 

Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29:767–9.

Article  CAS  Google Scholar 

Goltsov AY, Loseva JG, Andreeva TV, Grigorenko AP, Abramova LI, Kaleda VG, et al. Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia. Mol Psychiatry. 2006;11:325–6.

Article  CAS  PubMed  Google Scholar 

Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, et al. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta. 2007;380:186–90.

Article  CAS  PubMed  Google Scholar 

Morita Y, Ujike H, Tanaka Y, Otani K, Kishimoto M, Morio A, et al. A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia. Biol Psychiatry. 2007;61:1200–3.

Article  CAS  PubMed  Google Scholar 

Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1905–12.

Article  CAS  Google Scholar 

Hons J, Zirko R, Ulrychova M, Cermakova E, Doubek P, Libiger J. Glycine serum level in schizophrenia: Relation to negative symptoms. Psychiatry Res. 2010;176:103–8.

Article  CAS  PubMed  Google Scholar 

Labrie V, Wong AHC, Roder JC. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology. 2012;62:1484–503.

Article  CAS  PubMed  Google Scholar 

Coyle JT, Ruzicka WB, Balu DT. Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. Am J Psychiatry. 2020;177:1119–28.

Article  PubMed  PubMed Central  Google Scholar 

Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca B, Maj M. Plasma Concentrations of Amino Acids in Chronic Schizophrenics Treated with Clozapine. Neuropsychobiology. 2001;44:167–71.

Article  CAS  PubMed  Google Scholar 

Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, et al. Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett. 2014;582:93–8.

Article  CAS  PubMed  Google Scholar 

Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:1113–23.

Article  CAS  Google Scholar 

Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45.

Article  CAS